Indication
Metabolic Diseases
6 clinical trials
8 products
1 drug
Clinical trial
Multicenter, Open-Label, Multi-cohort Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Drug Product GNR 055 (JSC "GENERIUM", Russia) in Patients With Mucopolysaccharidosis Type IIStatus: Recruiting, Estimated PCD: 2025-02-01
Product
GNR-055Clinical trial
Endoscopic Sleeve Gastroplasty (ESG) Versus Glucagon-like Peptide 1 Receptor Agonist (GLP-1RA) Versus ESG + GLP-1RA in Patients With Obesity, Non-Alcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis: A Randomized Controlled TrialStatus: Not yet recruiting, Estimated PCD: 2025-07-01
Product
GLP1-RAClinical trial
GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGHStatus: Recruiting, Estimated PCD: 2027-05-31
Product
Oral SemaglutideClinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3561774 in Adults With Mixed DyslipidemiaStatus: Active (not recruiting), Estimated PCD: 2024-03-04
Product
LY3561774Drug
VarlilumabClinical trial
Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance TestStatus: Recruiting, Estimated PCD: 2024-08-01
Product
KisspeptinClinical trial
Open-label Multi-cohort Study of the Tolerability, Safety, and Pharmacokinetics of GNR-055 in Healthy Volunteers After a Single Intravenous Injection in Increasing DosesStatus: Completed, Estimated PCD: 2023-09-20
Product
Cohort 1Product
Cohort 2Product
Cohort 3